The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study

References

• Wellcome Trust. The growing crisis in antibiotic R&D: opportunities for G20 member action to support sustainable innovation 2020. https://wellcome.org/sites/default/files/the-growing-crisis-for-antibiotic-r-and-d.pdf. Accessed 28 May 2022.
   Google Scholar
• World Health Organization. 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva. Licence: CC BY-NC-SA 3.0 IGO; 2021.
   Google Scholar
• Renwick M, Mossialos EWhat are the economic barriers of antibiotic R&D and how can we overcome them?Expert Opin Drug Discov20181310889892 10.1080/17460441.2018.1515908 30175625
   PubMed Web of Science ®Google Scholar
• Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, et al.Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implicationsPharmacotherapy J Hum Pharmacol Drug Therapy.20173717184 10.1002/phar.1868
   Google Scholar
• DRIVE-AB. Revitalizing the antibiotic pipeline - Stimulating innovation while driving sustainable use and global access. 2018. http://drive-ab.eu/wp-content/uploads/2018/01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf. Accessed 25 May 2021.
   Google Scholar
• Renwick MJ, Brogan DM, Mossialos EA systematic review and critical assessment of incentive strategies for discovery and development of novel antibioticsJ Antibiot20166927388 1:CAS:528:DC%2BC28Xjt1Oku78%3D 10.1038/ja.2015.98
   PubMed Web of Science ®Google Scholar
• O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016.
   Google Scholar
• CIDRAP- Center for Infectious Disease Research and Policy. Plazomicin for tough infections: a tale of 2 clinical trials 2019. www.cidrap.umn.edu/news-perspective/2019/02/plazomicin-tough-infections-tale-2-clinical-trials.
   Google Scholar
• Nambiar S, Laessig K, Toerner J, Farley J, Cox EAntibacterial drug development: challenges, recent developments, and future considerationsClin Pharmacol Ther2014962147149 1:CAS:528:DC%2BC2cXht1aisbbO 10.1038/clpt.2014.116 25056394
   PubMed Web of Science ®Google Scholar
• Nambiar S, Cavaleri M, Sato JAchieving regulatory alignment for anti-infective clinical trialsACS Infect Dis20206613081310 1:CAS:528:DC%2BB3cXhtVOksbnN 10.1021/acsinfecdis.0c00270 32529834
   PubMed Web of Science ®Google Scholar
• Sinha MS, Kesselheim ASRegulatory incentives for antibiotic drug development: a review of recent proposalsBioorgan Med Chem2016242464466451 1:CAS:528:DC%2BC28XhsVKqsrrK 10.1016/j.bmc.2016.08.033
   PubMed Web of Science ®Google Scholar
• McAuslane N, Liberti L, Connelly PThe confluence of accelerated regulatory and health technology assessment access pathwaysClin Pharmacol Ther20191054935942 10.1002/cpt.1315 30472729
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. Document EMA/CHMP/594085/. 2016.
   Google Scholar
• European Medicines Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Document EMA/CHMP/351889/. 2013.
   Google Scholar
• European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. CPMP/EWP/558/95 rev 2. 2011.
   Google Scholar
• Food and Drug Administration. Qualified infectious disease product designation—questions and answers guidance for industry: Food and Drug Administration, U.S. Department of Health and Human Services 2018. https://www.fda.gov/media/148480/download. Accessed 25 May 2021.
   Google Scholar
• Food and Drug Administration. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases guidance for industry: U.S. Department of Health and Human Services; 2014. https://www.fda.gov/media/86250/download. Accessed 25 May 2021.
   Google Scholar
• Food and Drug AdministrationEstablishing a list of qualifying pathogens under the Food and Drug Administration Safety and Innovation Act. Final ruleFed Reg2014791083246432481
   PubMedGoogle Scholar
• Food and Drug Administration. Limited population pathway for antibacterial and antifungal drugs guidance for industry. 2018. https://www.fda.gov/media/113729/download. Accessed 25 May 2021.
   Google Scholar
• Kashoki M, Hanaizi Z, Yordanova S, Veselý R, Bouygues C, Llinares J, et al.A comparison of EMA and FDA decisions for new drug marketing applications 2014–2016: concordance, discordance, and whyClin Pharmacol Ther20201071195202 10.1002/cpt.1565 31306483
   PubMed Web of Science ®Google Scholar
• Hirako M, McAuslane N, Salek S, Anderson C, Walker SA comparison of the drug review process at five international regulatory agenciesDrug Inf J: DIJ/Drug Inf Assoc2007413291308 10.1177/009286150704100302
   Google Scholar
• Rawson NSTime required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996–1998CMAJ20001624501504 1:STN:280:DC%2BD3c7ms1ejsw%3D%3D 10701383 1231167
   PubMed Web of Science ®Google Scholar
• Rawson NSCanadian, European and United States new drug approval times now relatively similarRegul Toxicol Pharmacol201896121126 10.1016/j.yrtph.2018.05.002 29730446
   PubMed Web of Science ®Google Scholar
• Joppi R, Bertele V, Vannini T, Garattini S, Banzi RFood and Drug Administration vs European Medicines Agency: review times and clinical evidence on novel drugs at the time of approvalBr J Clin Pharmacol2020861170174 10.1111/bcp.14130 31657044
   PubMed Web of Science ®Google Scholar
• Alqahtani S, Seoane-Vazquez E, Rodriguez-Monguio R, Eguale TPriority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?Pharmacoepidemiol Drug Saf2015247709715 10.1002/pds.3793 26013294
   PubMed Web of Science ®Google Scholar
• Boucaud-Maitre D, Altman J-JDo the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort studyEur J Clin Pharmacol2016721012751281 1:CAS:528:DC%2BC28Xht12ls7zN 10.1007/s00228-016-2104-3 27473682
   PubMed Web of Science ®Google Scholar
• Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JSRegulatory review of novel therapeutics—comparison of three regulatory agenciesN Engl J Med20123662422842293 1:CAS:528:DC%2BC38XptFentL0%3D 10.1056/NEJMsa1200223 22591257 3504361
   PubMed Web of Science ®Google Scholar
• Dörr P, Wadworth A, Wang T, McAuslane N, Liberti LAn analysis of regulatory timing and outcomes for new drug applications submitted to Swissmedic: comparison with the US Food and Drug Administration and the European Medicines AgencyTher Innov Regul Sci Regul Sci2016506734742 10.1177/2168479016655841
   PubMed Web of Science ®Google Scholar
• The International Network of Agencies for Health Technology Assessment. HTA glossary. http://htaglossary.net/health+technology+assessment. Accessed 25 May 2021.
   Google Scholar
• Schaffer SK, West P, Towse A, Henshall C, Mestre-Ferrandiz J, Masterton R, et al.Assessing the value of new antibiotics: additional elements of value for health technology assessment decisions2017LondonThe Office of Health Economics
   Google Scholar
• Zentner A, Velasco-Garrido M, Busse R. Methods for the comparative evaluation of pharmaceuticals. GMS Health Technology Assessment. 2005;1.
   Google Scholar
• Angelis A, Lange A, Kanavos PUsing health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countriesEur J Health Econ2018191123152 10.1007/s10198-017-0871-0 28303438
   PubMed Web of Science ®Google Scholar
• Neri M, Hampson G, Henshall C, Towse A. HTA and payment mechanisms for new drugs to tackle AMR. 2019.
   Google Scholar
• Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al.How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countriesAppl Health Econ Health Policy2017153307321 10.1007/s40258-016-0300-z 28063134
   PubMed Web of Science ®Google Scholar
• Colson AR, Morton A, Årdal C, Chalkidou K, Davies SC, Garrison LP, et al. Antimicrobial resistance: is health technology assessment part of the solution or part of the problem? Value in Health. 2021.
   Google Scholar
• Kållberg C, Årdal C, Salvesen Blix H, Klein E, Martinez EM, Lindbæk M, et al.Introduction and geographic availability of new antibiotics approved between 1999 and 2014PLoS ONE20181310 10.1371/journal.pone.0205166 30325963 6191083
   PubMed Web of Science ®Google Scholar
• Vreman RA, Heikkinen I, Schuurman A, Sapede C, Garcia JL, Hedberg N, et al.Unmet medical need: an introduction to definitions and stakeholder perceptionsValue Health2019221112751282 10.1016/j.jval.2019.07.007 31708064
   PubMed Web of Science ®Google Scholar
• Boucher HW, Ambrose PG, Chambers H, Ebright RH, Jezek A, Murray BE, et al.White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needsJ Infect Dis20172162228236 1:CAS:528:DC%2BC1cXitFCqs7fI 10.1093/infdis/jix211 28475768 5853321
   PubMed Web of Science ®Google Scholar
• Morton A, Colson A, Leporowski A, Trett A, Bhatti T, Laxminarayan RHow should the value attributes of novel antibiotics be considered in reimbursement decision making?MDM Policy Pract2019422381468319892237 31910245 6935770
   PubMedGoogle Scholar
• Tong A, Sainsbury P, Craig JJIjfqihc. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. 2007;19(6):349–57.
   Google Scholar
• European Medicines Agency. Medicines. https://www.ema.europa.eu/en/medicines. Accessed 4 Oct 2022.
   Google Scholar
• Food and Drug Administration. Drugs@FDA: FDA Approved Drug Product. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 4 Oct 2022.
   Google Scholar
• World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. World Health Organization; 2017.
   Google Scholar
• Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al.Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosisLancet Infect Dis2018183318327 10.1016/S1473-3099(17)30753-3 29276051
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry expedited programs for serious conditions–drugs and biologics: Food and Drug Administration, U.S. Department of Health and Human Services; 2014. https://www.fda.gov/media/86377/download.
   Google Scholar
• European Medicines Agency London. PRIME: priority medicines. https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines. Accessed 25 May 2021.
   Google Scholar
• European Medicines Agency. Final report on the adaptive pathways pilot. European Medicines Agency London, UK; 2016.
   Google Scholar
• European Medicines Agency. Fast track routes for medicines that address unmet medical needs 2015. https://www.ema.europa.eu/en/news/fast-track-routes-medicines-address-unmet-medical-needs. Accessed 2 Mar 2023.
   Google Scholar
• Food and Drug Administration. Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals—Data Dictionary 2023. https://www.fda.gov/media/135308/download. Accessed 3 Mar 2023.
   Google Scholar
• European Medicines Agency. Innovative medicine 2023. https://www.ema.europa.eu/en/glossary/innovative-medicine. Accessed 5 Mar 2023.
   Google Scholar
• Food and Drug Administration. Novel Drug Approvals for 2022 2023. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022. Accessed 5 Mar 2023.
   Google Scholar
• European Medicines Agency. Veterinary regulatory 2023. https://www.ema.europa.eu/en/veterinary-regulatory/research-development/scientific-guidelines/novel-therapies. Accessed 5 Mar 2023.
   Google Scholar
• Nicod EWhy do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countriesEur J Health Econ2017186715730 10.1007/s10198-016-0823-0 27538758
   PubMed Web of Science ®Google Scholar
• Yin RKQualitative research from start to finish2015New YorkGuilford Publications
   Google Scholar
• Fusch PI, Ness LRAre we there yet? Data saturation in qualitative researchQualitative Rep20152091408
   Web of Science ®Google Scholar
• Braun V, Clarke VJQrip. Using thematic analysis in psychology. 2006;3(2):77-101
   Google Scholar
• Cassell C, Symon GEssential guide to qualitative methods in organizational research2004Thousand OaksSage 10.4135/9781446280119
   Google Scholar
• Bazeley PAnalysing qualitative data: more than ‘identifying themes’Malay J Qual Res200922622
   Google Scholar
• NVivo qualitative data analysis software, version 12.: QSR International Pty Ltd.; 2018 https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/home.
   Google Scholar
• Theuretzbacher UAntibiotic innovation for future public health needsClin Microbiol Infect20172310713717 1:STN:280:DC%2BC1cjitVagsg%3D%3D 10.1016/j.cmi.2017.06.020 28652114
   PubMed Web of Science ®Google Scholar
• Vella Bonanno P, Ermisch M, Godman B, Martin AP, Van Den Bergh J, Bezmelnitsyna L, et al.Adaptive pathways: possible next steps for payers in preparation for their potential implementationFront Pharmacol20178497 10.3389/fphar.2017.00497 28878667 5572364
   PubMed Web of Science ®Google Scholar
• Wallach JD, Ross JS, Naci HThe US Food and Drug Administration’s expedited approval programs: evidentiary standards, regulatory trade-offs, and potential improvementsClin Trials2018153219229 10.1177/1740774518770648 29871509
   PubMed Web of Science ®Google Scholar
• European Commission. EUnetHTA 2023. https://www.eunethta.eu/about-eunethta/. Accessed 8 Mar 2023.
   Google Scholar